Table 2 Main clinical features distribution and prevalence for age groups
From: Clinical and molecular characterization of 112 single-center patients with Neurofibromatosis type 1
Age groups in years | No | ≥6CALs | Ferecling | ≥2 CNFs | SCNFs | Plexiform neurofibromas | ≥2Lisch nodules | Dysmorphic features | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No | % | No | % | No | % | No | % | No | % | No | % | No | % | ||
0–1 | 6 | 6 | 100 | 2 | 33.3 | 1 | 16.6 | 1 | 16.6 | 0 | – | 0 | – | 1 | 16.6 |
2–4 | 11 | 9 | 81.8 | 3 | 27.3 | 2 | 18.1 | 0 | – | 1 | 9 | 1 | 9 | 5 | 45.4 |
5–18 | 78 | 74 | 94.8 | 13 | 16.6 | 8 | 10.2 | 4 | 5 | 1 | 1.3 | 7 | 9 | 4 | 5.2 |
19–30 | 9 | 9 | 100 | 4 | 44.4 | 6 | 66.6 | 2 | 22 | 0 | – | 1 | 11 | 0 | – |
31–60 | 8 | 5 | 62.5 | 1 | 12.5 | 5 | 62.5 | 1 | 12.5 | 2 | 25 | 2 | 25 | 0 | – |
Total | 112 | 103 | 92 | 23 | 20.5 | 22 | 19.6 | 8 | 7.1 | 4 | 3.5 | 11 | 10 | 10 | 9 |